# A Study Assessing HMB-002 in Participants With Von Willebrand Disease

> **NCT06754852** · PHASE1,PHASE2 · RECRUITING · sponsor: **Hemab ApS** · enrollment: 108 (estimated)

## Conditions studied

- Von Willebrand Disease (VWD)
- Von Willebrand Disease (VWD), Type 1
- Von Willebrand Disease (VWD), Type 2

## Interventions

- **DRUG:** HMB-002 (Part A)
- **DRUG:** HMB-002 (Part B)

## Key facts

- **NCT ID:** NCT06754852
- **Lead sponsor:** Hemab ApS
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-02-06
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 108 (ESTIMATED)
- **Last updated:** 2025-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06754852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06754852, "A Study Assessing HMB-002 in Participants With Von Willebrand Disease". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06754852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*